All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma hub is an independent medical education platform, sponsored by Sanofi, Bristol Myers Squibb, GSK and Roche, and supported through a grant from Janssen Biotech, Inc. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Belantamab mafodotin, a BCMA-targeted antibody-drug conjugate, has demonstrated efficacy in patients with multiple myeloma (MM). The phase III DREAMM-7 trial (NCT04246047) is assessing the safety and efficacy of belantamab mafodotin in combination with bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in patients with relapsed/refractory (R/R) MM with ≥1 prior line of therapy.1 Results from this trial were presented by Mateos1 during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. |
Key learnings: |
The DREAMM-7 study met its primary endpoint of progression-free survival (PFS): median PFS was 36.6 months vs 13.4 months in the BVd and DVd arms, respectively (p < 0.00001); this benefit was sustained across prespecified subgroups, including patients with lenalidomide-refractory or high-risk cytogenetic MM. |
BVd also improved overall survival (OS) vs DVd, with 12-month and 18-month OS rates of 87% vs 81% and 84% vs 73%, respectively. |
BVd was associated with a higher ≥complete response (CR) rate (34.6% vs 17.1%) and a higher ≥CR with measurable residual disease-negativity rate (24.7% vs 9.6%) when compared with DVd. |
The safety profile of BVd was consistent with that of the individual agents, and ocular adverse events were generally manageable, leading to discontinuation in 9% of patients. |
These results suggest that BVd could be a new standard of care for patients with R/R MM. |
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox